CD19 and B-cell non-Hodgkin lymphoma: To explore the ability of the assay to quantify bcfDNA, we applied it to plasma cfDNA samples extracted from five patients affected by relapsed/refractory B-cell lymphoma who received CD19 CAR T-cell therapy.